BioAge is a platform-driven, clinical-stage biotechnology company that is mapping human aging to develop a pipeline of therapies that treat disease and extend healthy lifespan. Our proprietary platform encompasses >65M molecular measurements spanning 45+ years of human aging and unlocks a universe of novel biological insights and druggable mechanisms for age-related disease. Our growing clinical-stage portfolio includes BGE-105, a first-in-class apelin receptor agonist that prevented muscle atrophy in a Ph1b study of older volunteers at bedrest. We are developing BGE-105 in parallel for ICU-related atrophies and for muscle preservation during GLP-1 weight loss therapy. The portfolio also includes novel internally discovered NLRP3 inhibitors for neurodegenerative and ocular diseases driven by inflammation. Our mission is to develop therapies that change the nature of aging and provide patients with years more healthy time. To date, BioAge has raised $127M from Andreessen Horowitz, Kaiser Foundation Hospitals, and others. BioAge offers a comprehensive compensation package, comprehensive health and wellness benefits (medical, dental, and vision insurance), childcare and fertility benefits, and a 401(k) retirement savings plan with matched employer contributions. We pride ourselves on giving employees many opportunities for career development, including a generous annual budget for continued learning and dedication to training and skill development. At BioAge, everyone matters, and we embrace diversity and differences while we learn from each other. We are an equal opportunity employer. BioAge prohibits discrimination and harassment of any type and affords equal employment opportunities to employees and applicants without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any other characteristic protected by law. BioAge conforms to the spirit as well as the letter of all applicable laws and regulations.
